Nektar Therapeutics presented Phase 2b data for its lead asset rezpegaldesleukin (REZPEG) at the 2026 American Academy of Dermatology Annual Meeting in Denver, Colorado, showing statistically significant improvements in both atopic dermatitis and alopecia areata cohorts.
In the atopic dermatitis cohort of 393 moderate‑to‑severe patients, every dose arm achieved both EASI‑75 and EASI‑90 responses, confirming the drug’s robust efficacy across the dose range and supporting the company’s plan to launch a Phase 3 program (ZENITH‑AD) in the second quarter of 2026.
In the alopecia areata cohort, the high‑dose arm (24 µg/kg q2w) produced a 28.2% mean reduction in SALT score versus 11.2% in placebo, and a 30% mean percent reduction versus 6% in placebo, meeting the study’s primary endpoint. A 36‑week extension showed a 30% mean percent reduction for both treatment arms versus 6% in placebo, with statistical significance (p < 0.05) after excluding four patients who did not meet baseline eligibility.
Nektar’s Q4 2025 earnings, released on March 12, 2026, beat expectations: revenue rose to $21.8 million from $10.61 million consensus, and the EPS loss of $1.78 surpassed the $2.52 estimate. The full‑year 2025 revenue of $55.2 million fell from $98.4 million in 2024, largely due to the sale of the Huntsville manufacturing facility, while the net loss of $164.1 million reflected ongoing R&D investment. Cash and investments stood at $245.8 million at year‑end, and a February 2026 secondary offering and ATM activity raised $476 million in net proceeds, positioning the company for the upcoming Phase 3 launch.
Howard W. Robin, President and CEO, said, “2025 was a pivotal year for Nektar as we saw successful and transformative Phase 2 data readouts for rezpegaldesleukin. The data highlighted the promise and differentiation of our novel Treg mechanism in two inflammatory dermatological disease settings of atopic dermatitis and alopecia areata. With our strengthened financial position following the recent financing, we look forward to initiating our Phase 3 program in atopic dermatitis in June of this year.”
Analysts have upgraded their outlooks, with a consensus “Strong Buy” rating from six analysts and price targets ranging up to $165.00, reflecting confidence in the drug’s clinical trajectory and the company’s improved financial footing.
REZPEG has received Fast Track designation from the FDA for both moderate‑to‑severe atopic dermatitis and severe alopecia areata, and the company’s competitive advantage lies in its selective Treg stimulation, which may offer a better safety profile than existing biologics such as dupilumab.
A class‑action lawsuit alleging securities fraud over patient enrollment in the REZOLVE‑AA program is pending, with a lead‑plaintiff deadline in May 2026, representing a potential legal headwind.
With the strong Phase 2b results, a robust financial base, and a clear roadmap to Phase 3, Nektar is positioned to advance REZPEG toward regulatory approval and potential partnership or commercialization opportunities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.